Synthesis and biological evaluation of Trifluoromethoxyphenyl Indole Carboxamide analogs, ADME and toxicity prediction

Synthesis and biological evaluation of Trifluoromethoxyphenyl Indole Carboxamide analogs, ADME and toxicity prediction

We report synthesis, ADME profile, and biological evaluation of new analogues as effective Anticancer Agents. Trifluoromethoxyphenyl indole-5-carboxamide analogues (4a-4m) were developed as a class of strong inhibitors of BCR-ABL1 kinase. The compounds (4c, 4e, and 4m) showed good anticancer activity in cancer cell lines such as MCF7, MV411 and K562 with IC50 values of 1.4 µM, 1.7 µM, and 1.1 µM, respectively. In human liver microsomes, these substances likewise displayed a favorable ADME profile, good solubility, and minimal clearance. In an oncology program these analogues offer a promising beginning for the development of BCR-ABL1 kinase inhibitors.

URN:NBN:sciencein.cbl.2024.v11.660

Synthesis and biological evaluation of Trifluoromethoxyphenyl Indole Carboxamide analogs, ADME and toxicity prediction – https://pubs.thesciencein.org/journal/index.php/cbl/article/view/a660

Chemical Biology Letters

Exploring Small-Molecule Inhibitors Targeting MAPK Pathway Components: Focus on ERK, MEK1, and MEK2 Kinases in Cancer Treatment

Exploring Small-Molecule Inhibitors Targeting MAPK Pathway Components: Focus on ERK, MEK1, and MEK2 Kinases in Cancer Treatment

Mitogen-activated protein kinases (MAPKs), also known as extracellular signal regulated kinases (ERKs), are found in numerous signal transduction pathways and are triggered by protein kinase cascades. This article will review the present state of MAPK pathway inhibitors, with an emphasis on the characteristics of tiny molecule blockers of the p38, MEK1, and MEK2 protein kinases. Many of these inhibitors have showed potential in experimental animal models of disease, and they are now being investigated in people for inflammatory and cancer diseases. Clinical trials are currently evaluating targeting a subset of cellular signaling cascades and signaling cascades that control pleiotropic cellular activity. These activities will have far-reaching consequences for the management of a wide range of disorders. The Ras-Raf-MEK-ERK (ERK) pathway, on the other hand, is a clear therapeutic target because it is a common downstream route for a range of critical growth factor tyrosine kinase receptors that are frequently changed or overexpressed in human malignancies. Several new medicines that target this route have been discovered and are currently being tested in clinical studies. BAY 43-9006 is one of the most intriguing new agents. Although it was initially created as a Raf kinase inhibitor, it also has the ability to target Flt-3, c-Kit, and VEGFR-2, which helps to explain its antiproliferative and antiangiogenic characteristics. The ERK signaling system in normal and malignant tissue will be discussed in this paper, with a focus on emerging treatments that target the ERK cascade at the Raf kinase level.

Exploring Small-Molecule Inhibitors Targeting MAPK Pathway Components: Focus on ERK, MEK1, and MEK2 Kinases in Cancer Treatment – https://pubs.thesciencein.org/journal/index.php/cbl/article/view/a659

Chemical Biology Letters

Remodeling of membrane lipid homeostasis in azole resistant isolates of Candida albicans

Remodeling of membrane lipid homeostasis in azole resistant isolates of Candida albicans

Azole resistance mechanisms in Candida albicans infections majorly focus around the alteration of target enzymes, overexpression of efflux pump proteins, and changes in lipid metabolism. Our earlier lipidomic studies have linked changes in cellular lipid compositions to drug susceptibilities and phenotypic defects. This study investigates the relationship between whole cell and membrane lipid profiles in isogenic drug-susceptible and resistant isolates of C. albicans. We have examined the fatty acid and sterol snapshot lipidomics in whole cells, plasma membrane, and lipid rafts. Correlations were discovered between these lipid compositions and the observed drug resistance in C. albicans. Although the correlations drawn from cellular and plasma membrane data corroborate, understanding plasma membrane and suborganellar (rafts in this case) lipid changes may provide better insights into their roles in efflux pump activities and localization, and drug susceptibilities.

URN:NBN:sciencein.cbl.2024.v11.658

Remodeling of membrane lipid homeostasis in azole resistant isolates of Candida albicans – https://pubs.thesciencein.org/journal/index.php/cbl/article/view/a658

Chemical Biology Letters

The ScienceIn Conference Fellowship

The fellowship for attending the National and International Science conferences and symposium in India.

The ScienceIN offers fellowship to support the scholars for attending the national and international science conferences and symposium in India. The ‘Conference Fellowship’ from The ScienceIN covers the full registration fee of participants (preferably young researchers – Ph.D. students, Research Associates, PDFs, and young faculty/scientists) via either waive off (for future sponsored conferences) or refund (already completed conferences).

At present 50 Conference Fellowships are available for the participants of the

CRSI – National Symposium in Chemistry – 32 held at BITS Pilani, Pilani 2-4 Feb 2024.

who are authors of either ‘Journal of Molecular Chemistry‘ and/or ‘Molecular Letters‘ .

The participants of the CRSI-NSC-32 can claim the refund of their registration fee (full – excluding other fee, if any) if they have published any article in JMC or ML (or can publish an article in JMC or ML before the last date (i.e. 31-Oct-24) for claim).
– Submit your registration fee slip (snap or online transfer details) and title of published article (JMC/ML) to the pubs@thesciencein.org for refund.
– Provide the bank details/upi id for online refund of your registration fee (the fellowship will be directly credited in Scholar’s account).
– One author from respective article will be eligible for refund.
– Articles published or accepted for publication before the last date of claim (31-Oct-2024) will be eligible of this fellowship.
– First come first served will be the process for disbursing the fellowships.
– It is for Indian Scholars only (fellowship in INR will be credited).

————-

All future announcements related to Conference fellowships will be on this page, scholars can visit this page for open fellowships for attending the science conference.

Author Guidelines for Biomedical and Therapeutics Letters journal

Authors guidelines for submission of manuscript, and article template for the Biomedical and Therapeutics Letters journal

Information for Authors

> The Authors need to submit a single manuscript file containing all figures and tables.
> The supplementary data files should be submitted as a separate file.
> A cover letter and graphical abstract should be submitted along with manuscript as details provided below.

Cover letter

Authors should supply a cover letter indicating rational of their work. Cover letter should also have details of at least three reviewers (with email). Cover letter should be provided on the first step of submission in “Comments for Editor’ box.

Graphical Abstract

Authors need to submit a graphical abstract highlighting the contents of manuscript. The guidelines for graphical abstract preparation and submission are available on this link.

Manuscript

Manuscript should include Title, Author (s), Affiliation (complete name of institutions), Abstract, 5 Keywords (refer https://pubs.thesciencein.org/content-composition for details), (other sections like Introduction, Results and discussion,  experimental procedures, conclusion in the main body text of manuscript could be used for full paper article), acknowledgment and references in the listed order. Short communications need not to be arranged in different sections. References should be formatted as shown for articles,1 theses,2 books,3,4 and patents,5

1. R. Ping, M. Laura, P.S. Mario. Title of the journal article should be included here. Int. Lett.Org. Chem. 1996, 61, 4439–4449.
2. B.K. Sharma. Ph.D. Dissertation, Thesis Title, Cornell University, 1995.
3. R. Hussain, D. Shinkoi. Title of book like Synthesis and application of ionic liquid, John Wiley & Sons: New York, 2010.
4. R.S. Buchanod, D.K. Reddy. In Selective Organic Transformations; T.R. Thyagarajan, Ed.; Integrated science: New York, 2002; Vol. 2, pp 1–95.
5. G.L. Loyale, U.S. Patent 5 934 456, 1998; Chem. Abstr. 1998, 65, 2870.

Citation Manager style files: Authors are highly encouraged to use the citation manager programs for citing and formatting the references. Authors may use Mendelay, Zotero, Paper 2 or Endnote program. If you are using any of these citation manager program for Bibliography (References and Notes), then you can download citation style file for journal (common for all ScienceIn journals):

Mendelay, Zotero, Paper 2 style file: ScienceIn Journals CSL style file

Authors can directly add the styles to Zotero and Mendeley, follow the below steps:
Zotero: Open Zotero desktop > Edit (top menu)> Preferences > Cite (menu in new opened small window) > Get additional styles.. (click this link below the list of styles) > in new opened window – search the term ‘Integrated Science’ in search box and then click on ‘Integrated Science Publishing Journals’ link > style file will download > Open the file with Zotero desktop and use (this style is common for all ScienceIn Journals).
Mendeley: Open Mendeley desktop > View (top menu) > Citation Styles > More styles.. > go to tab ‘Get more styles’ (in new opened window) > search for the term ‘Integrated Science’ in search box and then click on ‘install’ adjacent to ‘Integrated Science Publishing Journals’ list > style file will be installed > then click on ‘Use this style’ from the installed styles tab and use (this style is common for all ScienceIn Journals).

Endnote style file: ScienceIn Journals Endnote style file

(click and download the endnote style file from google drive … and either copy the file to Endnote style folder (go to C:>Program files>Endnote > Style folder > paste the file in this folder (it will listed in style when you open the Endnote program) or you can directly Open the downloaded style file in EndNote program and use).

Also the user can check the respective program user guide (online link on Zotero, Mendeley or Endnote) regarding information on how to use the style file.

Submission

Authors need to submit all manuscripts through journal website. Register by following link ‘Register’ on the journal site https://pubs.thesciencein.org/journal/index.php/btl (make sure to mark checked the options Author and reviewer while registering for journal). On login, you will find ‘new submission’ link in your panel page.

For review purpose, author can submit the manuscript as outlined above. However, Authors are advised to prepare their manuscript according to journal article template (provided below) as it progress towards acceptance. On acceptance of manuscript, authors must need to supply their manuscript in Article template (if they have not already submitted in template).

Templates

On acceptance of manuscript, Authors are required to submit revised manuscript in journal articles template (If authors wish, they are free to submit their manuscript in journal article template while submitting first time).

Download the template, double click the file to open, prepare your article and save it with your own name.

Instructions for conversion of manuscript in journal article template is provided on https://pubs.thesciencein.org/manuscript-conversion-in-journal-article-template-instructions/  (please check the video on the link for correctly formatting your manuscript.

Login and submit the manuscript online (submission by email are not accepted). Only online submissions are accepted now.

Authors are advised to contact Support, BTL (email: pubs @ thesciencein.org ) if there is any problem in registration or submission.

Unique IDs for Articles: The journal is currently using URN number for the published articles (however, this is currently meant for internal use by journal). The journal will process the assigning of DOI (Digital Object Indentifier) to articles (including previously published ones) once the journal is indexed in Web of Science (Clarivate) as it help in providing the correct citations records for the published articles.

Declaration of Conflict of Interest

Authors should mention any conflict of interest in the work submitted to Biomedical and Therapeutics Letters. The statement about conflict of interest may be mentioned in the ‘Letter to editor’ and placed in the manuscript after acknowledgement section.

Authors need to check the details of ‘Conflict of Interest’ for authors of scientific works.

Ethical Uses Declaration

If the manuscript report the experimentation on animals (including clinical trials on human beings), then declaration about ethical way handling of animals and about keeping the complete privacy of human identity (in case of clinical trials) must be mentioned in the manuscript.

Helsinki Declaration (contents from NIH-NLM): When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should be asked to indicate whether the institutional and national guide for the care and use of laboratory animals was followed. See the detailed instructions on https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/  and https://www.wma.net/policy/current-policies/ (for recent applicable policy documents).

Authors need to check and follow the general Ethical Practices for Authors of scientific work.

Submission Journal Link

Submit manuscript on journal editorial processing site at

https://pubs.thesciencein.org/journal/index.php/btl  ( New journal site with new platform ).

SGVU – Biotechnology and Biomedical Sciences

A special issue on recent advancements in the field of Biotechnology and Biomedical Sciences encompassing research endeavours related to drug discovery and design, therapeutic delivery systems and approaches, structural/cell/immuno-biology, bioinformatics, nano-/bio-materials, biosensors and biomedical devices, environmental remediation and toxicology, agricultural biotechnology and application of artificial intelligence/machine learning tools for better health and safe environment.

Article Submission: 10-May-2024

Issue Completion: 30-August-2024

Authors need to submit their articles to guest editors/conference secretariat for preliminary evaluation and peer -reviewing. Final accepted article will have to be submitted on (the recommended) respective journal site).

Design, synthesis and biological evaluation of novel sulfamoyl benzamides as allosteric activators of human glucokinase

Design, synthesis and biological evaluation of novel sulfamoyl benzamides as allosteric activators of human glucokinase

Glucokinase (GK) activators, which target the GK enzyme, are an emerging class of therapeutics with promising effects against diabetes. The objective of this work was to create a new group of sulfamoyl benzamide derivatives with the ability to activate GK and evaluate their effectiveness in treating diabetes. From benzoic acid, several compounds containing sulfamoyl benzamide scaffold were synthesized and evaluated for their ability to activate GK in an in vitro enzymatic experiment. In silico docking analyses were employed to explore how the most suitable arrangements in the allosteric area of the GK enzyme interact during binding. The effectiveness of the identified substances in reducing high blood sugar levels was assessed using the oral glucose tolerance test (OGTT) in healthy rats. This evaluation was based on the results of laboratory tests on enzymes and in silico simulations. One of the most active compounds from the antihyperglycemic assay was then tested for its antidiabetic effects in an induced diabetic rat OGTT assay. The in vitro GK activation was best among compounds 1, 6, and 8 (activation fold: 2.03-2.09). In the OGTT assay (normal rats), compounds 1 and 6 showed promising antihyperglycemic activity. In vivo antidiabetic assay confirmed the consistency with in silico and in vitro outcomes. The newly synthesized derivatives of sulfamoyl benzamide have the potential to be used as a basis for the development of further GK activators that are both safe and efficacious and can be administered orally. These activators may be used as therapeutic agents to treat type 2 diabetes.

URN:NBN:sciencein.cbl.2024.v11.657

Design, synthesis and biological evaluation of novel sulfamoyl benzamides as allosteric activators of human glucokinase – https://pubs.thesciencein.org/journal/index.php/cbl/article/view/a657

Chemical Biology Letters

Molecular pathways with role to play in oral cancer: A mini-review

Molecular pathways with role to play in oral cancer: A mini-review

Oral cancer is the sixth most prevalent type of cancer worldwide and third in India out of the different cancer types identified. Mouth and oral cancers collectively refer to cancers of the buccal cavity, lips, oropharynx, hypopharynx, and larynx. Genetic anomalies, the upregulation of several proteins, the deregulation of tumor-suppressive and oncogenes, and risk factors like alcohol and tobacco consumption are a few examples of the known irregularities that contribute to the development of oral cancer through the accumulation of various carcinogenic substances. Oral cancer is caused and developed by multiple molecular and cellular pathways such as PI3K/AKT/mTOR, Ras-Raf-MEK-ERK pathway, Wnt signaling, NF-κB pathway, Hippo pathway, etc. In addition, various genes including TP53, PTEN, CDKN2A, HRAS, PIK3CA, NOTCH1, IRF6, TP63, etc. are also involved in this malignancy. Therefore, it is crucial to have a deep understanding of these pathways to properly understand the development of oral cancer. This short review focuses on compiling together various signaling and molecular pathways accountable for oral carcinoma development.

URN:NBN:sciencein.cbl.2024.v11.652

Molecular pathways with role to play in oral cancer: A mini-review – https://pubs.thesciencein.org/journal/index.php/cbl/article/view/a652

Chemical Biology Letters

Synthesis of Indole-Oxadiazole coupled isoxazole hybrids as potent EGFR targeting anticancer agents

Synthesis of Indole-Oxadiazole coupled isoxazole hybrids as potent EGFR targeting anticancer agents

The synthesis of new indole-oxadiazole coupled isoxazole hybrids (6a–o) synthesized by the Cu(I)-catalyzed reaction of in situ generated nitrile oxides with 3-(3,5-dichloro-4-methoxyphenyl)-5-(1-(prop-2-yn-1-yl)-1H-indol-3-yl)-1,2,4-oxadiazole in good yields have been reported here. The chemical structures of all newly synthesized hybrids were confirmed by 1H-NMR, 13C-NMR, and Mass spectra. All synthesized compounds were screened for their in vitro cytotoxicity against two breast cancer cell lines MCF-7 and MDA-MB-231 respectively. All the derivatives were more active against MCF7 than MDA-MB-231 cancer cells and few compounds showed better activity than the standard erlotinib. The ability of more potent compounds to inhibit EGFR tyrosine kinase, one of the key enzymes involved in breast carcinomas was evaluated by in vitro enzymatic assay and it was found that the compound (6g) and (6m) had more inhibitory activity IC50 values 0.311±0.05 and 0.203±0.03 mM than erlotinib (IC50=0.421±0.03 mM).

URN:NBN:sciencein.cbl.2024.v11.651

Synthesis of Indole-Oxadiazole coupled isoxazole hybrids as potent EGFR targeting anticancer agents – https://pubs.thesciencein.org/journal/index.php/cbl/article/view/a651

Chemical Biology Letters

Synthesis of 1,4-disubstituted-1,2,3-Triazole derivatives for investigation of inhibition and molecular docking studies against Xanthine Oxidase

Synthesis of 1,4-disubstituted-1,2,3-Triazole derivatives for investigation of inhibition and molecular docking studies against Xanthine Oxidase

This study evaluates the inhibition effect of new 1,4-disubstituted-1,2,3-triazoles against Xanthine Oxidase supplemented by molecular modelling. Nine compounds of 1,4-disubstituted-1,2,3-triazoles by Sharpless’s approach have been synthesized in this report. The structures of the synthesized compounds were characterized using FT-IR, 1H and 13C-NMR and Mass spectroscopies Among these synthesized molecules (5-bromothiophen-2-yl)(1-(3-fluorobenzyl)-1H-1,2,3-triazole-4-yl)methanone (9f) and (5-Bromothiophen-2-yl(1-(4-methoxybenzyl)-1H-1,2,3-triazole-4-yl)methanone (9h) showed better activity against Xanthine oxidase (XO) compared to allopurinol. In the light of the XO inhibition results, triazoles having of ketone moiety (9f-i) were found to be more active than triazoles of ketone-free (9a-e). These results were supported by docking models. The docking calculations of the target XO with nine available compounds showed good binding energies with favourable binding interactions. These findings were particularly evident that 9f (BE -7.29 kcal/mol) and 9h (BE -7.59 kcal/mol) are represented encouraging higher inhibition properties towards xanthine oxidase (XO), compared to allopurinol as a reference compound. Significant binding energies and interactions obtained by performing the docking studies are demonstrated, in particular, that the compounds 9f and 9h may be more potential bio compounds than the positive compounds, allopurinol, and febuxostat.

URN:NBN:sciencein.cbl.2023.v10.628

Synthesis of 1,4-disubstituted-1,2,3-Triazole derivatives for investigation of inhibition and molecular docking studies against Xanthine Oxidase – https://pubs.thesciencein.org/journal/index.php/cbl/article/view/a628

Chemical Biology Letters